{"id":"loratadine","rwe":[],"_fda":{"id":"4fd50f17-7237-4659-bad6-a9e6189fa37c","set_id":"0038bc38-c205-4d8d-ab78-1abbcd76829e","openfda":{"unii":["7AJO3BO7QN"],"route":["ORAL"],"rxcui":["311372"],"spl_id":["4fd50f17-7237-4659-bad6-a9e6189fa37c"],"brand_name":["allergy relief"],"spl_set_id":["0038bc38-c205-4d8d-ab78-1abbcd76829e"],"package_ndc":["59779-612-46","59779-612-72","59779-612-75","59779-612-58","59779-612-39","59779-612-76","59779-612-70","59779-612-95","59779-612-49","59779-612-03","59779-612-88","59779-612-65","59779-612-60","59779-612-78"],"product_ndc":["59779-612"],"generic_name":["LORATADINE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["LORATADINE"],"manufacturer_name":["CVS Pharmacy"],"application_number":["ANDA076301"],"is_original_packager":[true]},"purpose":["Purpose Antihistamine"],"version":"15","stop_use":["Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away."],"warnings":["Warnings Do not use if you have ever had an allergic reaction to this product or any of its ingredients Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose. When using this product do not take more than directed. Taking more than directed may cause drowsiness. Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away. If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)"],"questions":["Questions or comments? 1-800-719-9260"],"ask_doctor":["Ask a doctor before use if you have liver or kidney disease. Your doctor should determine if you need a different dose."],"do_not_use":["Do not use if you have ever had an allergic reaction to this product or any of its ingredients"],"when_using":["When using this product do not take more than directed. Taking more than directed may cause drowsiness."],"effective_time":"20260225","active_ingredient":["Active ingredient (in each tablet) Loratadine 10 mg"],"inactive_ingredient":["Inactive ingredients lactose monohydrate, magnesium stearate, povidone, pregelatinized starch"],"storage_and_handling":["Other information • do not use if printed foil under cap is broken or missing • store between 20 ° to 25 ° C (68 ° to 77 ° F)"],"indications_and_usage":["Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: • runny nose • itchy, watery eyes • sneezing • itching of the nose or throat"],"dosage_and_administration":["Directions adults and children 6 years and over 1 tablet daily; not more than 1 tablet in 24 hours children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor"],"spl_product_data_elements":["allergy relief Loratadine LORATADINE LORATADINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE POVIDONE, UNSPECIFIED L612"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)"],"dosage_and_administration_table":["
adults and children 6 years and over1 tablet daily; not more than 1 tablet in 24 hours
children under 6 years of ageask a doctor
consumers with liver or kidney diseaseask a doctor
"],"package_label_principal_display_panel":["Principal Display Panel CVS ™ 24 HR RELIEF actual size Non-Drowsy † ALLERGY RELIEF Loratadine Tablets, 10 mg, Antihistamine Compare to Claritin ® active ingredient Original Prescription Strength 30 TABLETS 24-Hour Relief of: Sneezing, Runny nose, Itchy & watery eyes, Itchy throat or nose Indoor & Outdoor Allergies † When taken as directed. See Drug Facts Panel. cvs-allergy-relief-carton-image.jpg"]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Coronary arteriosclerosis","Diabetes mellitus","Disease of liver","Hepatic failure","Hypertensive disorder","Hypertensive urgency","Hyperthyroidism","Impaired renal function disorder","Kidney disease","Retention of urine"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT01469234","NCT00550550","NCT02339714","NCT00946608","NCT07300735","NCT06955741","NCT01507792","NCT05275933","NCT02545361","NCT01007864","NCT03883386","NCT02932774","NCT06531707","NCT00524836","NCT01311336","NCT00762983","NCT02495077","NCT02305979","NCT07380178","NCT00972738","NCT07101445","NCT00730912","NCT01390441","NCT00561717","NCT00525382","NCT05263206","NCT04179461","NCT00963573","NCT03372473","NCT01055756","NCT05190627","NCT00796211","NCT00525278","NCT00837915","NCT03517943","NCT00866788","NCT00776282","NCT04162795","NCT00721331","NCT06396013","NCT00423995","NCT05421416","NCT02576808","NCT04633967","NCT01228630","NCT06217367","NCT05043350","NCT05265910","NCT00319995","NCT06870292"],"aliases":["Claritin","Alavert","Clarityn"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3542/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$129","description":"LORATADINE 10 MG ODT","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=loratadine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:33:38.294282+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:33:43.744211+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=loratadine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:33:44.207425+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:37.187991+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:37.188024+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:33:45.349477+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL998/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:33:44.968746+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA076301","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:37.188028+00:00"}},"allNames":"claritin","offLabel":[],"timeline":[],"aiSummary":"Loratadine (Claritin) is a second-generation, non-sedating antihistamine first approved in 1993. Now OTC and available generically worldwide, it provides 24-hour allergy relief with once-daily dosing and minimal drowsiness.","brandName":"Claritin","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1","novelty":"","modality":"Small molecule","drugClass":"Second-generation antihistamine","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:33:47.106906+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally Schering-Plough)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"loratadine","indications":{"approved":[{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic idiopathic urticaria","diseaseId":"chronic-idiopathic-urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Common cold","diseaseId":"common-cold","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal congestion","diseaseId":"nasal-congestion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal discharge","diseaseId":"nasal-discharge","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Seasonal allergic rhinitis","diseaseId":"seasonal-allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sneezing","diseaseId":"sneezing","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vasomotor rhinitis","diseaseId":"vasomotor-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01469234","phase":"Phase 4","title":"A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":255,"indication":"Rhinitis","completionDate":"2011-11"},{"nctId":"NCT00550550","phase":"Phase 3","title":"A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy With SCH 697243 (Phleum Pratense) in Children 5 to <18 Years of Age ","status":"COMPLETED","sponsor":"ALK-Abelló A/S","isPivotal":true,"enrollment":345,"indication":"Rhinoconjunctivitis, Rhinitis","completionDate":"2009-09"},{"nctId":"NCT02339714","phase":"Phase 2","title":"Effect Comparison of Acupuncture Combined With Moxibustion and Loratadine for Perennial Allergic Rhinitis: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Zhao Hong","isPivotal":false,"enrollment":98,"indication":"Rhinitis, Allergic, Perennial","completionDate":"2018-06"},{"nctId":"NCT00946608","phase":"Phase 1","title":"Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Sandoz Inc. and Schering (Claritin) 10 mg Loratadine Tablets In Healthy Adult Male Volunteers Under Fed and Fasting Condi","status":"COMPLETED","sponsor":"Sandoz","isPivotal":false,"enrollment":30,"indication":"Allergy","completionDate":"2005-08"},{"nctId":"NCT07300735","phase":"NA","title":"A Comparative Study of Diosmin-Hesperidin and Loratadine for the Prevention of G-CSF Induced Bone Pain in Patients With Hematological Malignancies","status":"RECRUITING","sponsor":"Alexandria University","isPivotal":false,"enrollment":88,"indication":"Hematologic Malignancy, Neutropenia","completionDate":"2026-07"},{"nctId":"NCT06955741","phase":"Phase 1","title":"A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of BMS-986446, an Anti-MTBR Tau","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":46,"indication":"Healthy Volunteer","completionDate":"2025-09-11"},{"nctId":"NCT01507792","phase":"NA","title":"Effect of Iron Repletion in Women With Chronic Cough and Iron Deficiency","status":"COMPLETED","sponsor":"University of Turin, Italy","isPivotal":false,"enrollment":22,"indication":"Cough, Laryngeal Disease","completionDate":"2011-01"},{"nctId":"NCT05275933","phase":"Phase 2","title":"Assessing the Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang as Adjuvant Treatment in Mild COVID-19 Patients on Home Recovery Program in Singapore: a Randomised, Double-blind, Placebo-controlled","status":"COMPLETED","sponsor":"Singapore Chung Hwa Medical Institution","isPivotal":true,"enrollment":93,"indication":"COVID-19","completionDate":"2023-11-22"},{"nctId":"NCT02545361","phase":"Phase 1","title":"A Phase 1/2a, Multi-center, Dose Escalation, 2 Stages Study to Evaluate the Safety, Tolerability, and Anti-cancer Activity of Subcutaneously Administered KAHR-102 for the Treatment of Lymphoma Patient","status":"WITHDRAWN","sponsor":"Kahr Medical","isPivotal":false,"enrollment":0,"indication":"Lymphoma","completionDate":"2020-04"},{"nctId":"NCT01007864","phase":"Phase 3","title":"Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","isPivotal":true,"enrollment":80,"indication":"Idiopathic Parkinson's Disease","completionDate":"2011-12"},{"nctId":"NCT03883386","phase":"Phase 2","title":"Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use","status":"TERMINATED","sponsor":"University of Michigan","isPivotal":false,"enrollment":3,"indication":"Bone Pain","completionDate":"2019-10-18"},{"nctId":"NCT02932774","phase":"Phase 4","title":"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment ","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","isPivotal":false,"enrollment":683,"indication":"Allergic Rhinitis, Hay Fever","completionDate":"2001-07"},{"nctId":"NCT06531707","phase":"Phase 3","title":"Efficacy and Safety of Ibuprofen/Loratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold","status":"RECRUITING","sponsor":"Laboratorios Silanes S.A. de C.V.","isPivotal":true,"enrollment":177,"indication":"Common Cold","completionDate":"2025-02-20"},{"nctId":"NCT00524836","phase":"Phase 3","title":"A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Perennial Allergic Rhinitis.","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":71,"indication":"Rhinitis, Allergic","completionDate":"2004-02"},{"nctId":"NCT01311336","phase":"Phase 2","title":"Randomized Phase II Pilot Study of Loratadine for the Prevention of Pain Caused by the Granulocyte Colony Stimulating Factor Pegfilgrastim","status":"UNKNOWN","sponsor":"University of Vermont","isPivotal":false,"enrollment":55,"indication":"Pegfilgrastim-induced Back and Leg Pain","completionDate":"2013-06"},{"nctId":"NCT00762983","phase":"N/A","title":"Claritin® Tablet 10 mg, Claritin® RediTabs® 10 mg, Claritin® Dry Syrup 1% Drug Use Investigation (Pediatrics)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":1003,"indication":"Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial","completionDate":"2009-02"},{"nctId":"NCT02495077","phase":"Phase 2","title":"Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":290,"indication":"Kidney Transplant","completionDate":"2021-07-23"},{"nctId":"NCT02305979","phase":"N/A","title":"Evaluation of Loratadine for Granulocyte-Colony Stimulating Factor Induced Bone Pain in Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":61,"indication":"Leukemia, Lymphoma","completionDate":"2017-09"},{"nctId":"NCT07380178","phase":"NA","title":"The Effect of Apple Fruit Extract (Malus Sylvestris Mill) as an Antioxidant and Anti-Inflammatory on Allergic Rhinitis","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","isPivotal":false,"enrollment":40,"indication":"Rhinitis, Allergic, Perennial","completionDate":"2025-07-05"},{"nctId":"NCT00972738","phase":"Phase 3","title":"A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":1214,"indication":"Seasonal Allergic Rhinitis","completionDate":"2001-07"},{"nctId":"NCT07101445","phase":"Phase 4","title":"Prevent Allergic Reactions to Aphexda With Dexamethasone (PARADE)","status":"RECRUITING","sponsor":"Emory University","isPivotal":false,"enrollment":94,"indication":"Multiple Myeloma","completionDate":"2027-12-31"},{"nctId":"NCT00730912","phase":"Phase 4","title":"Protocol for Post-approval Commitment Study of Loratadine for PPK Analysis in Japanese Pediatric and Adults Patients","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":261,"indication":"Perennial Allergic Rhinitis","completionDate":"2008-12"},{"nctId":"NCT01390441","phase":"Phase 1","title":"A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":100,"indication":"Rheumatoid Arthritis","completionDate":"2014-04"},{"nctId":"NCT00561717","phase":"Phase 4","title":"A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal A","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":70,"indication":"Seasonal Allergic Rhinitis","completionDate":"2008-02"},{"nctId":"NCT00525382","phase":"Phase 3","title":"A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU)","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":134,"indication":"Urticaria","completionDate":"2004-03"},{"nctId":"NCT05263206","phase":"Phase 3","title":"Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Un","status":"RECRUITING","sponsor":"Sanofi","isPivotal":true,"enrollment":284,"indication":"Pruritus","completionDate":"2027-08-25"},{"nctId":"NCT04179461","phase":"Phase 2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma: Bench to Community","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","isPivotal":false,"enrollment":21,"indication":"Asthma in Children","completionDate":"2019-10-03"},{"nctId":"NCT00963573","phase":"Phase 4","title":"Efficacy and Safety of Loratadine-Betamethasone Oral Solution (1 mg/0.05 mg/1 mL) for Initial Treatment of Severe Perennial Allergic Rhinitis in School Age Children","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":100,"indication":"Rhinitis","completionDate":"2006-11"},{"nctId":"NCT03372473","phase":"Phase 3","title":"Safety and Efficacy of Montelukast + Loratadine vs. Montelukast for the Control of Mild to Moderate Persistent Asthma in Children: Randomized Controlled Clinical Trial","status":"COMPLETED","sponsor":"Innovacion y Desarrollo de Estrategias en Salud","isPivotal":true,"enrollment":80,"indication":"Asthma in Children","completionDate":"2017-06-30"},{"nctId":"NCT01055756","phase":"Phase 3","title":"","status":"WITHDRAWN","sponsor":"Azidus Brasil","isPivotal":true,"enrollment":0,"indication":"Allergic Rhinitis","completionDate":"2010-06"},{"nctId":"NCT05190627","phase":"Phase 2","title":"Phase II Clinical Trial Evaluating the Effect of Loratadine Associated to Rapamicyn in Patients With Lymphangioleiomyomatosis","status":"UNKNOWN","sponsor":"Institut d'Investigació Biomèdica de Bellvitge","isPivotal":false,"enrollment":62,"indication":"Lymphangioleiomyomatosis","completionDate":"2023-12-30"},{"nctId":"NCT00796211","phase":"Phase 2","title":"A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Zalicus","isPivotal":false,"enrollment":20,"indication":"Plaque Psoriasis","completionDate":"2009-01"},{"nctId":"NCT00525278","phase":"Phase 3","title":"Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":67,"indication":"Rhinitis, Allergic","completionDate":"2003-10"},{"nctId":"NCT00837915","phase":"NA","title":"Comparative, Randomized, Single-Dose, Fully Replicated, 4-Way Crossover Bioavailability Study of Ranbaxy and Schering (Claritin_D® 24 Hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Rel","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":"2002-11"},{"nctId":"NCT03517943","phase":"Phase 1","title":"A Randomized, Crossover Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5mg/Pseudoephedrine Sulfate 120 mg, M","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":29,"indication":"Clinical Pharmacology","completionDate":"2018-08-30"},{"nctId":"NCT00866788","phase":"Phase 2","title":"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihist","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":90,"indication":"Chronic Idiopathic Urticaria","completionDate":"2010-01"},{"nctId":"NCT00776282","phase":"NA","title":"An Open Label, Balanced, Randomized, Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover, Bioavailability Study on Loratadine Formulations Comparing Loratadine 10 mg Orally Disintegrating ","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","isPivotal":false,"enrollment":80,"indication":"Healthy","completionDate":"2006-09"},{"nctId":"NCT04162795","phase":"Phase 4","title":"An Open Label, Multi-center Study to Evaluate Sensory Attributes of an Antihistamine Product","status":"COMPLETED","sponsor":"Bayer","isPivotal":false,"enrollment":468,"indication":"Allergic Rhinitis","completionDate":"2019-11-13"},{"nctId":"NCT00721331","phase":"Phase 1","title":"A Phase I, Single-Center, Randomized, Vehicle-Controlled Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Zalicus","isPivotal":false,"enrollment":20,"indication":"Atopic Dermatitis","completionDate":"2008-09"},{"nctId":"NCT06396013","phase":"Phase 1","title":"A Multicentre Randomized Controlled Clinical Study on the Chitosan Nanocrystalline Qinteng Huoxue Runji Ointment Therapy for Psoriasis With Blood Stasis Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Hospital of Traditional Chinese Medicine","isPivotal":false,"enrollment":96,"indication":"Plaque Psoriasis","completionDate":"2026-07-31"},{"nctId":"NCT00423995","phase":"Phase 3","title":"Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":379,"indication":"Seasonal Allergic Rhinitis","completionDate":"2007-03-10"},{"nctId":"NCT05421416","phase":"Phase 2","title":"Loratadine for the Prevention of Bone Pain Caused by Granulocyte Colony Stimulating Factor (G-CSF) During Stem Cell Mobilization","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","isPivotal":false,"enrollment":78,"indication":"Stem Cell Transplant Complications","completionDate":"2026-12-01"},{"nctId":"NCT02576808","phase":"Phase 2","title":"Comparative Study of Efficacy and Adverse Effects of Ginger Extract and Loratadine for Treatment of Allergic Rhinitis Patients (Clinical Trial Phase II)","status":"COMPLETED","sponsor":"Thai Traditional Medical Knowledge Fund","isPivotal":false,"enrollment":80,"indication":"Rhinitis,Allergic","completionDate":"2017-10"},{"nctId":"NCT04633967","phase":"N/A","title":"Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.","status":"COMPLETED","sponsor":"Maritime Neurology","isPivotal":false,"enrollment":30,"indication":"Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis","completionDate":"2021-02-28"},{"nctId":"NCT01228630","phase":"Phase 3","title":"Randomized Clinical Study for Efficacy Assessment Between Cloratadd-D, Loratadine + Pseudoephedrine (Coated Pill), Produced by EMS S/A Laboratories and Allegra-D , Produced by Sanofi-Aventis for Patie","status":"COMPLETED","sponsor":"Azidus Brasil","isPivotal":true,"enrollment":156,"indication":"Perennial Allergic Rhinitis","completionDate":"2012-05"},{"nctId":"NCT06217367","phase":"Phase 4","title":"Do Common Over-the-counter Antihistamine Medications Modify Thermoregulatory Responses During Passive Heat Stress?","status":"UNKNOWN","sponsor":"Lakehead University","isPivotal":false,"enrollment":16,"indication":"Heat Illness, Allergic Rhinitis","completionDate":"2024-06"},{"nctId":"NCT05043350","phase":"Phase 2","title":"Potential Therapeutic Outcome of Combined Antihistaminics Therapy in COVID 19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","isPivotal":true,"enrollment":214,"indication":"Covid19","completionDate":"2022-07-30"},{"nctId":"NCT05265910","phase":"Phase 4","title":"A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With ","status":"COMPLETED","sponsor":"Andover Research Eye Institute","isPivotal":false,"enrollment":58,"indication":"Allergic Conjunctivitis","completionDate":"2022-04-23"},{"nctId":"NCT00319995","phase":"Phase 3","title":"Efficacy and Safety of Combination Loratadine/Montelukast QD vs Pseudoephedrine and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":1095,"indication":"Rhinitis, Allergic, Seasonal","completionDate":"2006-06-28"},{"nctId":"NCT06870292","phase":"NA","title":"Assessment of the Effectiveness and Safety of Posterior Nasal Nerve Combined with Anterior Ethmoid Neurotomy in Patients with Idiopathic Rhinitis: a Multicentre, Randomised, Parallel-controlled Study","status":"RECRUITING","sponsor":"Xu Yu","isPivotal":false,"enrollment":150,"indication":"Idiopathic Rhinitis","completionDate":"2026-12-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once daily","formulation":"Tablet, Orally disintegrating tablet, Liquid"},"crossReferences":{"chemblId":"CHEMBL998"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1386,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"firstApprovalDate":"1993-04-12","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:33:47.106906+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}